title: Viral oncolysate in the management of malignant melanoma. II. Clinical studies.
abstract: Melanoma cell oncolysate, prepared with Newcastle disease virus, was administered as an immunostimulant to 13 patients with metastatic melanoma. The oncolysate was well tolerated. Six treated patients evidenced a decrease in the size of skin nodules or diseased lymph nodes. Visceral lesions were not favorably influenced to any marked degree. One case of fulminating disease showed a change to slow progression and survived a year longer than was otherwise expected. Another patient, whose melanoma could not be controlled by surgery or chemotherapy, has been in complete remission for 2 years. It appears that viral oncolysate might be particularly helpful to patients with early disease.
mesh_terms: D000328:Adult; D000368:Aged; D000956:Antigens, Viral / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000628:therapy; D009522:Newcastle disease virus; D012075:Remission, Spontaneous; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*; D014780:Viruses
chemical_list: D000956:Antigens, Viral; D000970:Antineoplastic Agents